BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...readouts disclosed at June’s European Hematology Association Congress. bluebird bio Inc....
...Therapeutics Inc. Cellectis S.A. Nanjing Bioheng Biotech Co. Ltd. Celyad S.A. bluebird bio Inc. CRISPR...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

...of different types of hemoglobin, sickling propensity, and metabolic markers such as ATP and 2,3-DPG. bluebird bio Inc....
...of RBCs.TARGETSPKR - Pyruvate kinase isoenzyme R BCL11A - B cell CLL lymphoma 11A Karen Tkach Tuzman bluebird bio Inc. CRISPR...
BioCentury | Nov 6, 2020
Regulation

Nov. 5 Quick Takes: Setback for bluebird sinks shares; plus Cellectis, CRISPR, REMS, Novocure

...to buy up to an additional $75 million in notes. BC Staff Zynteglo (LentiGlobin BB305 gene therapy, Betibeglogene autotemcel) bluebird bio CRISPR...
BioCentury | Nov 6, 2020
Regulation

Pressure builds for Celgene payout as BMS faces possible liso-cel delay

...Celgene deal, via Celgene’s 2013 partnership with bluebird bio Inc....
BioCentury | Nov 5, 2020
Product Development

Data Byte: BCMA stands out at ASH 2020

...consistently reported higher response rates than their closest competitor in the BCMA CAR T race, bluebird bio Inc....
...the study. That patient and three others experienced Grade ≥ 3 infections. Lauren Martz Johnson & Johnson Allogene Therapeutics Inc. bluebird bio Inc. Tumor...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

...for that COVID has caused a multi-year delay.”bluebird bio Inc....
BioCentury | Oct 2, 2020
Regulation

After COVID-related delays, first approval may come in Europe for bluebird’s Lenti-D

...first approval by March 2021. On Friday, bluebird bio Inc....
...$2.20 to $51.65 on Friday. Amanda Micklus Lenti-D gene therapy bluebird bio Gene...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...Sachiyo Minegishi as CFO; Minegishi was most recently VP, lead for sickle cell disease at bluebird bio Inc....
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

...for bluebird-BMS program could fulfill CVR goalFDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc....
BioCentury | Sep 16, 2020
Emerging Company Profile

Graphite launches with $45M series A to use CRISPR-Cas9 for targeted gene integration

...LentiGlobin sickle cell gene therapy program at bluebird bio Inc....
Items per page:
1 - 10 of 391
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...readouts disclosed at June’s European Hematology Association Congress. bluebird bio Inc....
...Therapeutics Inc. Cellectis S.A. Nanjing Bioheng Biotech Co. Ltd. Celyad S.A. bluebird bio Inc. CRISPR...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

...of different types of hemoglobin, sickling propensity, and metabolic markers such as ATP and 2,3-DPG. bluebird bio Inc....
...of RBCs.TARGETSPKR - Pyruvate kinase isoenzyme R BCL11A - B cell CLL lymphoma 11A Karen Tkach Tuzman bluebird bio Inc. CRISPR...
BioCentury | Nov 6, 2020
Regulation

Nov. 5 Quick Takes: Setback for bluebird sinks shares; plus Cellectis, CRISPR, REMS, Novocure

...to buy up to an additional $75 million in notes. BC Staff Zynteglo (LentiGlobin BB305 gene therapy, Betibeglogene autotemcel) bluebird bio CRISPR...
BioCentury | Nov 6, 2020
Regulation

Pressure builds for Celgene payout as BMS faces possible liso-cel delay

...Celgene deal, via Celgene’s 2013 partnership with bluebird bio Inc....
BioCentury | Nov 5, 2020
Product Development

Data Byte: BCMA stands out at ASH 2020

...consistently reported higher response rates than their closest competitor in the BCMA CAR T race, bluebird bio Inc....
...the study. That patient and three others experienced Grade ≥ 3 infections. Lauren Martz Johnson & Johnson Allogene Therapeutics Inc. bluebird bio Inc. Tumor...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

...for that COVID has caused a multi-year delay.”bluebird bio Inc....
BioCentury | Oct 2, 2020
Regulation

After COVID-related delays, first approval may come in Europe for bluebird’s Lenti-D

...first approval by March 2021. On Friday, bluebird bio Inc....
...$2.20 to $51.65 on Friday. Amanda Micklus Lenti-D gene therapy bluebird bio Gene...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...Sachiyo Minegishi as CFO; Minegishi was most recently VP, lead for sickle cell disease at bluebird bio Inc....
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

...for bluebird-BMS program could fulfill CVR goalFDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc....
BioCentury | Sep 16, 2020
Emerging Company Profile

Graphite launches with $45M series A to use CRISPR-Cas9 for targeted gene integration

...LentiGlobin sickle cell gene therapy program at bluebird bio Inc....
Items per page:
1 - 10 of 391